Xero is a high-quality ANZ/UK SaaS cash machine taking a controversial, dilutive swing at the US via Melio—creating a “priced-for-failure” setup with large upside if execution holds.
Overview
As of Jan 13, 2026, Xero is at a pivotal moment: it is shifting from a pure-play SaaS ledger product into an active financial platform that monetizes payment flows and automates financial operations with AI. This pivot was crystallized by the US$2.5b acquisition of Melio, a controversial but strategic attempt to crack North America—where Xero has historically struggled against Intuit—by using embedded bill-pay and bank-led syndication distribution rather than fighting a direct accountant-channel war. Operationally, Xero still shows “compounder” characteristics: FY25 revenue grew ~23% and H1 FY26 operating revenue rose 20% to ~NZ$1.194b; gross margin remained elite at ~88.5%; and free cash flow margin expanded to ~26.9%, with Rule of 40 at ~44.5%. However, the stock has sold off sharply and trades well below key moving averages as investors apply a “prove it” discount, focusing on integration risk, dilution from the discounted capital raise, and governance friction around remuneration. The report’s stance is Overweight/accumulate for patient investors: the ANZ/UK franchise provides downside support, while successful Melio execution creates significant upside optionality.